Recently, TLR4/NF-κB has been implicated in EMs due to the critical regulatory roles of inflammation, indicating that targeting TLR4/NF-κB might be a strategy for EMs therapy. This evidence concerns the gene NFKB1 and eosinophilia-myalgia syndrome.